MAPT and Alzheimer disease: The NH226-44 amino acidic stretch, which is the minimal biological active moiety of parental 20–22 kDa NH2-truncated tau form(s) (Amadoro et al., 2010, 2012; Corsetti et al., 2015) has been recently recognized as one among the potentially targetable tau epitopes for promising Alzheimer’s disease immunotherapeutic interventions, being largely represented into CSF samples (Barthélemy et al., 2016a, b; Sato et al., 2018) and in autoptic specimens from affected subjects (Borreca et al., 2018).